Equibles does not estimate personal net worth.
Get an email with a short summary when Fennec Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get FENC alertsAdrian Haigh is recorded as COO at Fennec Pharmaceuticals Inc. (FENC) since August 3, 2023. Fennec Pharmaceuticals Inc. reported in an 8-K filed July 2, 2024 that Adrian Haigh resigned as Chief Operating Officer, effective June 30, 2024. Fennec Pharmaceuticals Inc. reported in an 8-K filed August 4, 2023 that Adrian Haigh was appointed Chief Operating Officer, effective August 3, 2023. Adrian Haigh has spoken on 3 earnings calls across 1 company, most recently for Fennec Pharmaceuticals Inc. on May 14, 2024. Fennec Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Fennec Pharmaceuticals Inc. includes Jeff Hackman (Board Member) and Jeffrey S. Hackman (Board Member).
“On June 30, 2024, Adrian Haigh departed from his position as Fennec Pharmaceuticals Inc.'s (the "Company") Chief Operating Officer, a role Mr. Haigh transitioned to in August 2023 after serving nine years as an independent director of the Company.”
“Adrian has been a board member of Fennec since 2014 and with his appointment to the management team of Fennec will step down as board member.”
“As Rosty has said, in the first quarter, our sales force has switched the focus of their activities to the community-treated adolescent and young adult (AYA) population that falls within our label.”
“As a reminder, we estimate that in the US, there are approximately 3,500 on-label pediatric oncology patients. The majority of these are treated in the specialist pediatric centers and receive an average of 12 vials per patient.”
“It has indeed been an exciting first few months since I joined Fennec full-time as Chief Operating Officer.”
2023-08-03–present
Start not stated–2024-06-30
Biotechnology · Healthcare
COO
2023-08-03–present
